(Date:11/23/2009)...ire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDL...7,2009astheex-dividenddateforits$200millionspecial...ontransactioncompletedonNovember2,2009.Thedividend...rdontherecorddate,December1,2009.NASDAQhassettheap...eofcommonstockforpurposesoftheex-dividenddateonNov...
(Date:11/23/2009)...DesignC or p.(IDC)announcedtodaythatDr.BruceL.A.Ca...uccessfultrackrec or dinbiotechnologyexecutivemana...Genetics,inSeattle,WAandChiefScientificOfficeratNo...://www.newscom.com/cgi-bin/prnh/20091123/SF15228 )...Officercommented,"IamdelightedtowelcomeDr.BruceCar...
(Date:11/23/2009)...all/--CornerstoneTherapeuticsInc.(Nasdaq: CRTX ),a...evelopingandcommercializingsignificantproductsprim...ncedthatCraigA.Collard,PresidentandChiefExecutiveO...AnnualPiperJaffrayHealthCareConferenceat3:30PMETon...ewYorkCity. ,, AliveaudioandarchivedwebcastofCo...
(Date:11/20/2009)...irstCall/ -- Dendreon Corporation (Nasdaq: DNDN )...istration (FDA) provided written acknowledgement t...ation (BLA) for PROVENGE® (sipuleucel-T) is a...iption Drug User Fee Act (PDUFA) date of May 1, 20...ended BLA. Dendreon is seeking licensure for PROV...
Breaking Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3...d, Ph.D., Joins as Chief Executive Officer, MENLO...y, Inc. (FAB), a privately held biotechnology comp...ies B financing. Prior investor SV Life,Sciences (...lta Partners.,The proceeds from the financing will...synthesis technology to produce biologic drugs and...
...urg Regional Education Consortium Promoting Advanc..., Dec. 7 High school and,college students from th...anced technology careers and curriculum through a ...s and the commonwealth., At BioTech Day 2007, hos...chnology, Community and Economic Development Deput...
...D, Calif., Dec. 7 Ardea Biosciences,Inc. (Nasdaq:...ief Executive,Officer, Barry D. Quart, PharmD, wil...eatment" panel discussion at the RBC Capital Marke...er 12, 2007 at 1:30 p.m. (ET) at,the Westin Times ...t of the,presentation and panel discussion will be...
Other Biology Technology:Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 2Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 3Capital Area Biotechnology Partnership Receives $160,000 State Investment 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 3ZOOM IPGRunner Mini-cell from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Agarose, Type C from Calbiochem
Assay Diluent from BD Biosciences Pharmingen
Biology Products: